Noxopharm (ASX:NOX) announces today that Dr Greg Van Wyk is departing the business. Dr Van Wyk, who has been with Noxopharm for 10 months and was initially employed as its Chief Medical Officer, has worked with Executive Chairman, Dr Graham Kelly, to build an experienced management team dedicated to bringing Veyonda through clinical trials and towards marketing approval.
For more information, download the attached PDF.
Download this document
